Christopher Connolly, MD
Family Medicine · Omaha, NENPI 1881616167
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,916 of the $12,285 with a category attached, or 80.7%. 55 manufacturers reported payments, led by AbbVie at 32.3% of the total. Among family medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$1K
- Amgen$840
- Lilly USA, LLC$834
- Pfizer$650
- AstraZeneca$639
- plus $4K from 49 others
What the payments were for
- Speaking & faculty fees$2,25018%
- Food & beverage$9,91681%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,285 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 168 | $135,840 |
| OzempicSemaglutide | 91 | $95,921 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $58,178 |
| JardianceEmpagliflozin | 69 | $51,212 |
| TrulicityDulaglutide | 35 | $43,538 |
| XareltoRivaroxaban | 38 | $40,689 |
| MounjaroTirzepatide | 36 | $40,191 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $29,938 |
| FarxigaDapagliflozin Propanediol | 33 | $27,730 |
| JanuviaSitagliptin Phosphate | 17 | $21,174 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $16,744 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,067 |
| Bydureon BciseExenatide Microspheres | 13 | $11,536 |
| MyrbetriqMirabegron | 14 | $9,166 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $7,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $650 | $135,840168 claims |
| Novo NordiskOzempic | $1,324 | $95,92191 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $834 | $83,72971 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $393 | $64,46395 claims |
| Boehringer IngelheimJardiance | $91 | $51,21269 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $639 | $44,47461 claims |
| Johnson & JohnsonXarelto | $360 | $40,68938 claims |
| MerckJanuvia | $59 | $21,17417 claims |
| Astellas Pharma US IncMyrbetriq | $230 | $9,16614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Omaha
- Gerard StanleyOmaha$50K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
- Paul VanaOmaha$12K
- Stephen TetraultOmaha$11K
- James RamigOmaha$11K
- Jeffrey RappOmaha$10K
- Christine Carlson RahnOmaha$10K
- Joseph DumbaOmaha$10K
- Charles RogersOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.